Personal experience and outcomes through one year following implantation of second generation trabecular micro-bypass stents in patients with open-angle glaucoma

Session Details

Session Title: Glaucoma I

Session Date/Time: Sunday 11/09/2016 | 14:30-16:00

Paper Time: 15:06

Venue: Auditorium C6

First Author: : F.Hengerer GERMANY

Co Author(s): :    T. Kohnen   I. Conrad-Hengerer                 

Abstract Details

Purpose:

The purpose of this work is to summarize findings through 1 year postoperative in patients with open-angle glaucoma following implantation of second generation trabecular micro-bypass stents.

Setting:

Department of Ophthalmology, Goethe-University Frankfurt am Main, Frankfurt, Germany

Methods:

This was a consecutive series of cases in which the iStent inject (Glaukos), a second generation trabecular micro-bypass stent, was implanted. Twenty-nine phakic or pseudophakic eyes of 22 patients with open-angle glaucoma (OAG) received two iStent inject devices as a sole procedure. The stents were implanted ab internally into Schlemm’s canal through a clear corneal incision using a single insertion instrument. A preoperative exam and postoperative exams through 1 year included assessment of IOP and medication use, and safety assessments including best corrected visual acuity (BCVA), cup-disk (C/D) ratio, complications, and secondary surgeries

Results:

Mean preoperative age was 71.1 ± 10.8 years, mean C/D ratio was 0.8 ± 0.1, and mean IOP was 24.3 ± 4.9 mmHg. Eighty-three percent of eyes used 3 or 4 medications; 38% had prior glaucoma surgery. Patients underwent implantation of 2 iStent inject devices without surgical complications. Mean IOP decreased to 13.8 ± 1.8 mmHg at one year, and mean medication use decreased by 2.4 medications from 2.8 preoperatively. At 1 year, 95% of eyes were using no or 1 medication. Postoperative progression of cataract was observed in 2 eyes; 95% of eyes had 1-year BCVA 20/40 or better.

Conclusions:

Substantial reduction in both IOP and medication use and favorable safety was reported through 1 year postoperative following implantation of 2 iStent inject devices as the solitary surgical procedure in eyes with OAG not controlled by previous medical and/or surgical therapy. A 43% (10.5 mmHg) decrease from preoperative medicated mean IOP and an 86% decrease in medication burden was observed at 1 year.

Financial Disclosure:

NONE